Maravai LifeSciences (NASDAQ:MRVI) Announces Earnings Results

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) issued its earnings results on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01), Briefing.com reports. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business had revenue of $46.85 million during the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences's quarterly revenue was down 26.9% compared to the same quarter last year. Maravai LifeSciences updated its FY 2025 guidance to EPS.

Maravai LifeSciences Trading Up 7.1%

NASDAQ MRVI opened at $2.12 on Tuesday. Maravai LifeSciences has a twelve month low of $1.67 and a twelve month high of $11.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The stock has a market cap of $539.19 million, a price-to-earnings ratio of -1.29 and a beta of 0.19. The firm's 50 day moving average price is $2.15 and its two-hundred day moving average price is $4.15.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MRVI. Bank of America dropped their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. UBS Group lowered their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Robert W. Baird lowered shares of Maravai LifeSciences from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $9.00 to $3.00 in a research note on Wednesday, February 26th. Morgan Stanley lowered their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 25th. Finally, Baird R W lowered shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $6.34.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.